{"id":924904,"date":"2026-01-07T09:26:25","date_gmt":"2026-01-07T14:26:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/"},"modified":"2026-01-07T09:26:25","modified_gmt":"2026-01-07T14:26:25","slug":"genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/","title":{"rendered":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Supports Genmab\u2019s ambition to build an AI-enabled innovation model that advances the company\u2019s vision of bringing transformative antibody medicines to patients<\/b><\/li>\n<\/ul>\n<p>COPENHAGEN, Denmark&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.genmab.com&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=Genmab+A%2FS&amp;index=1&amp;md5=fdc5512eba4bf0812bd1529be9f5ed64\"><b>Genmab A\/S<\/b><\/a><b> (Nasdaq: GMAB) announced<\/b><b>today a partnership with Anthropic to advance and enhance the company\u2019s research and development (R&amp;D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities.<\/b><\/p>\n<p>\nUnder the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab&#8217;s clinical development priorities. Genmab&#8217;s teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab\u2019s clinical programs as they progress toward key regulatory milestones.<\/p>\n<p>\n&#8220;This partnership represents a step forward in Genmab\u2019s transformation toward a more scalable, efficient, and digitally enabled R&amp;D engine aligned with the company\u2019s AI strategy,\u201d said Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab. &#8220;By reducing manual burden and enabling greater scale across our operations, our partnership with Anthropic will empower our teams to focus more time on high-value scientific and strategic work, with the goal of accelerating our path to patient impact.&#8221;<\/p>\n<p>\nGenmab continues to advance several late-stage investigational antibody medicines across solid tumors and hematological malignancies and is investing in state-of-the-art digital and AI-driven capabilities that will further support the expansion and execution of its growing pipeline.<\/p>\n<p>\n&#8220;Clinical development is critical, heavily regulated, and directly tied to patient outcomes. This is why we\u2019re partnering with an innovative and patient-focused biotech company like Genmab as they apply AI to support their clinical development process,\u201d said Kate Jensen, Head of Americas at Anthropic. \u201cWe&#8217;re working closely with Genmab to deploy Claude and build custom agentic solutions with the intention to help their team focus on the hard problems that require human expertise and get therapies to patients faster.\u201d<\/p>\n<p><b>About Genmab<\/b><\/p>\n<p>\nGenmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody\u2013drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab\u2019s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.<\/p>\n<p>\nEstablished in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DPxrb0jBGEpZVp5eQVRx92jNkmaVSsts0_MldrdZ96_VEBSpwK86DMOhrQEQ7wJMOQrfb4EOk4fpGk74y49QyYw%3D%3D&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=Genmab.com&amp;index=2&amp;md5=b53196fbfa98037745c0e765c3e27566\">Genmab.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgenmab&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=00febb41fb96085ffd0952030ff9223a\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGenmab&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=62619b0fc5720098449724d14138fb27\">X<\/a>.<\/p>\n<p><i>This Media Release contains forward looking statements. The words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend\u201d and \u201cplan\u201d and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab\u2019s most recent financial reports, which are available on <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.genmab.com%2F&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=www.genmab.com&amp;index=5&amp;md5=c40eff2f15acc898d941f1322bcfc661\"><i>www.genmab.com<\/i><\/a><i \/><i>and the risk factors included in Genmab\u2019s most recent Annual Report on Form 20-F and other filings <\/i><i>with the U.S. Securities and Exchange Commission (SEC), which are available at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2Fsearch-filings&amp;esheet=54390661&amp;newsitemid=20260107361677&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=4a54af1fef37b2847ce771c37cd0e90e\"><i>www.sec.gov<\/i><\/a><i>. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.<\/i><\/p>\n<p><i>Genmab A\/S and\/or its subsidiaries own the following trademarks: Genmab<sup>\u00ae<\/sup>; the Y-shaped Genmab logo<sup>\u00ae<\/sup>; Genmab in combination with the Y-shaped Genmab logo<sup>\u00ae<\/sup>; HuMax<sup>\u00ae<\/sup>; DuoBody<sup>\u00ae<\/sup>; HexaBody<sup>\u00ae<\/sup>; DuoHexaBody<sup>\u00ae<\/sup>, HexElect<sup>\u00ae <\/sup>and KYSO<sup>\u00ae<\/sup>.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260107361677\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260107361677\/en\/<\/a><\/span><\/p>\n<p>\nJyoti Sharma, Director, Global Communications &amp; Corporate Affairs<br \/>\n<br \/>T: +1 609 480 9844; E: <a rel=\"nofollow\" href=\"mailto:jysh@genmab.com\">jysh@genmab.com<\/a><\/p>\n<p>\nAndrew Carlsen, Vice President, Head of Investor Relations<br \/>\n<br \/>T: +45 3377 9558; E: <a rel=\"nofollow\" href=\"mailto:acn@genmab.com\">acn@genmab.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Denmark Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Other Health General Health Pharmaceutical Oncology Technology Artificial Intelligence Clinical Trials Science Biotechnology Other Technology Health Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260107361677\/en\/2684692\/3\/Genmab_Logo_Color_CMYK_2022.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence Supports Genmab\u2019s ambition to build an AI-enabled innovation model that advances the company\u2019s vision of bringing transformative antibody medicines to patients COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announcedtoday a partnership with Anthropic to advance and enhance the company\u2019s research and development (R&amp;D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab&#8217;s clinical development priorities. Genmab&#8217;s teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab\u2019s clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924904","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence Supports Genmab\u2019s ambition to build an AI-enabled innovation model that advances the company\u2019s vision of bringing transformative antibody medicines to patients COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announcedtoday a partnership with Anthropic to advance and enhance the company\u2019s research and development (R&amp;D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab&#8217;s clinical development priorities. Genmab&#8217;s teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab\u2019s clinical &hellip; Continue reading &quot;Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T14:26:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence\",\"datePublished\":\"2026-01-07T14:26:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/\"},\"wordCount\":826,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/\",\"name\":\"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-01-07T14:26:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/","og_locale":"en_US","og_type":"article","og_title":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk","og_description":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence Supports Genmab\u2019s ambition to build an AI-enabled innovation model that advances the company\u2019s vision of bringing transformative antibody medicines to patients COPENHAGEN, Denmark&#8211;(BUSINESS WIRE)&#8211;Genmab A\/S (Nasdaq: GMAB) announcedtoday a partnership with Anthropic to advance and enhance the company\u2019s research and development (R&amp;D) processes through the adoption of cutting-edge artificial intelligence (AI) capabilities. Under the agreement, Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab&#8217;s clinical development priorities. Genmab&#8217;s teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab\u2019s clinical &hellip; Continue reading \"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T14:26:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence","datePublished":"2026-01-07T14:26:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/"},"wordCount":826,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/","name":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-01-07T14:26:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260107361677r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genmab-partners-with-anthropic-to-accelerate-research-and-development-through-agentic-artificial-intelligence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924904"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924904\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}